Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04191135
Title Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

triple-receptor negative breast cancer


Carboplatin + Gemcitabine + Pembrolizumab

Carboplatin + Gemcitabine + Olaparib + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | CAN

No variant requirements are available.